drugset / Trial / NCT00976066

[11C]Carfentanil PET Study of GSK1521498

NCT00976066

Phase 1 Completed 26 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to determine whether GSK1521498 attaches to sites in the brain called mu-opioid receptors that are involved in the liking reactions to palatable high fat and high sugar foods. We hope that blocking these receptors may modify certain behaviours that may lead to obesity.

Timeline

Start
2009-06-15
Primary completion
2009-12-07
Completion
2009-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1521498 Small molecule Oral
Comparator Naltrexone Small molecule Oral

Indications